-transparent.png){kind=logo}
Ipratropium bromide is a bronchodilator whose effect has been compared with beta agonists but not with theophylline. Twelve asthmatics were given four two-week courses of the different combinations of ipratropium (40 micrograms in two puffs), theophylline capsules, and their corresponding placebos in a random, double-blind fashion. There was a significant increase in FEV1 and MMFR 60 minutes after theophylline was administered (p less than 0.05) when measured after one and two weeks of therapy. FEV1 and MMFR were significantly increased (p less than 0.05) 30 and 60 minutes after ipratropium inhalation and this increase was significantly greater when the patient had also been taking theophylline compared with placebo capsules (p less than 0.05). There was no toxicity associated with this combination. The synergism demonstrated may be related to the time sequence of drug administration, mechanical or cellular factors.
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
June 1997,
Chest,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
June 1978,
Chest,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
January 1983,
Arzneimittel-Forschung,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
December 1981,
Agents and actions,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
June 1986,
Archives of disease in childhood,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
August 1987,
Archives of disease in childhood,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
August 1988,
The American journal of the medical sciences,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
February 1981,
British medical journal (Clinical research ed.),
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
August 1981,
The Medical journal of Australia,
H Kreisman, and
H Frank, and
N Wolkove, and
M Gent
December 1979,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
